Roche Holding AG

ROG

CH0012032048

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,605

Sector

Pharmaceuticals

Calendar

10:00am - European Association for the Study of Diabetes Meeting

Related indices

SMI , STOXX Europe 600 Index (EUR)

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ROCHE HOLDING : Strong Q2 led to a guidance upgrade

July 25, 2024 at 12:00 pm EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

263.00CHF

Average target price

296.42CHF

Spread / Average Target

+12.71%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe Europe Other stock markets 04:57:11 2024-09-13 am EDT			5-day change	1st Jan Change
266.35 ^CHF	+1.27%		-2.95%	+8.83%

10:17am	ROCHE HOLDINGS AG : Deutsche Bank lowers its rating to Sell	ZD
10:15am	Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy	MT

ROCHE HOLDINGS AG : Deutsche Bank lowers its rating to Sell	04:17am	ZD
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy	04:15am	MT
Roche: FDA approves Tecentriq Hybreza	02:07am	CF
Roche Obtains US FDA Approval for Tecentriq Hybreza Subcutaneous Cancer Immunotherapy	01:34am	MT
FDA Approves Roche?s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy	01:00am	CI
Genentech Receives FDA Approval for Cancer Treatment	08:17pm	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza? With ENHANZE® for Multiple Types of Cancer	2024-09-12	CI
Roche: collaboration agreement with Qritive in AI	Sep. 12	CF
ECB to cut rates without lowering its guard	Sep. 12
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects -- Update	Sep. 12	DJ
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects	Sep. 12	DJ
Roche shares drop on side effects result in early-stage obesity pill trial	Sep. 12	RE
European shares jump 1% on tech boost; ECB meet in focus	Sep. 12	RE
ROCHE HOLDINGS AG : Receives a Sell rating from Goldman Sachs	Sep. 12	ZD
The mood is getting heavier, but Taylor Swift is keeping watch	Sep. 11
Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE
ROCHE HOLDINGS AG : UBS remains Neutral	Sep. 10	ZD
Roche Opens New Research Center in Switzerland	Sep. 10	MT
Roche inaugurates R&D center in Basel	Sep. 10	CF
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	Sep. 10	ZD
ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating	Sep. 10	ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	Sep. 09	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	Sep. 09	ZD
Swiss Market Index Kicks Off ECB Rate Decision Week in Green	Sep. 09	MT
Moody's Affirms Roche's Ratings on Strong Business Profile	Sep. 09	MT

Roche Holding AG

Equities

ROG